Porokeratosis Market Research Report – Forecast to 2027

Porokeratosis Treatment Market Research Report: By Type ((DSAP), Linear Porokeratosis, Peoddn, Others), by Diagnosis & Treatment (Biopsy, 5-Fluorouracil, Photodynamic Therapy, Retinoids, Cryotherapy, Lasers, Others), End-User – Global Forecast Till 2027

ID: MRFR/Pharma/4609-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Forecast

Global Porokeratosis Treatment Market is expected to gain prominence over the forecast period. The market is expected to register a CAGR of ~6.0% from 2018 to 2023. Various factors such as rising cases of renal transplant, improved reimbursement policies in developed countries, growing research funding, and rising competition among market players are continuously contributing to the growth of the global porokeratosis treatment market.   

Multiple treatment options have been suggested for porokeratosis such as medications, cryotherapy, photodynamic therapy, and lasers. Among all the treatment approaches used for the treatment of porokeratosis, laser therapy is attracting a great deal of attention. In case of malignant lesions, excision of benign lesions is often used, but it may leave scars. So, as an alternative, the CO2 laser therapy, Nd: YAG laser, and ruby laser appear to be a promising option for the treatment of porokeratosis.

Owing to the appealing aspects about laser therapy such as no incision and no hospitalization, the adoption of laser therapy for the treatment of porokeratosis is found to be rising which further drives the growth of the market.

Despite these drivers, there are some issues associated with the porokeratosis treatment market. The high cost of laser systems, lack of skilled or trained physicians, side effects associated with drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

The porokeratosis treatment market is currently dominated by various major players. Coherent, Inc. is one of them, by holding a strong share globally. In November 2016, Coherent, Inc. acquired Rofin. Rofin is one of the world’s leading developers and manufacturers of high-performance industrial laser sources and laser-based solutions and components. Various other mergers & acquisitions have been noticed lately in the porokeratosis market. Many such developments are expected to boost the market growth.

Key Players

Some of the key players in the global porokeratosis treatment market are Angiodynamics, Inc. (U.S.), Allergan (Republic of Ireland), Alma Lasers (Israel), Beiersdorf AG (Germany), Biogen (U.S.), Biolase Inc. (U.S.), Coherent, Inc. (U.S.), Coty Inc. (U.S.), Cutera (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (U.S.), IPG Photonics Corporation (U.S.), IRIDEX Corp. (U.S.), L’Oreal (France), Lumenis (U.S.), Pfizer (U.S.), PhotoMedex, Inc. (U.S.), Valeant Pharmaceuticals (Canada), and others.

Segmentation

The global porokeratosis treatment market is segmented


on the basis of type of porokeratosis, diagnosis and treatment, and end-user.


By type of porokeratosis, the market is classified as Disseminated Actinic Porokeratosis (DSAP), linear porokeratosis, porokeratosis of mantoux, Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN), and punctate porokeratosis.


Based on diagnosis and treatment, the market is classified as diagnosis and treatment. The diagnosis segment is further classified as biopsy, differential diagnosis, and others. The sub-segments of differential diagnosis include squamous cell carcinoma, lichenoid keratosis, and epidermal nevus. The treatment segment is further classified as topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-Fluorouracil, immunomodulators, photodynamic therapy, retinoids, cryotherapy, lasers, immunosuppressive agents, and others. The sub-segments of immunomodulators include imiquimod and resiquimod. The sub-segments of retinoids include topical retinoids and oral retinoids. The sub-segments of immunosuppressive agents include calcineurin inhibitors and others.


By end-user, the market is classified as hospitals and clinics, diagnostic centers, drug stores, research and academic institutes, and others.


Geographically, the global porokeratosis treatment market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American porokeratosis treatment market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.


The European porokeratosis treatment market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.


The Asia Pacific porokeratosis treatment market is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia Pacific.


The Middle Eastern and African porokeratosis treatment market is segmented into the Middle East and Africa.


Regional Market Summary


Global Porokeratosis Treatment Market Share, by Region, 2017 (%)


 Porokeratosis Treatment Market Share


Source: MRFR Analysis


The Americas dominates the porokeratosis treatment market owing to the rising prevalence of disseminated superficial actinic porokeratosis and increasing renal transplant cases, as around 10.68% of renal transplant recipients suffered from porokeratosis. According to the National Kidney Foundation, Inc., in 2014, 17,107 kidney transplants took place in the U.S. Moreover, advanced diagnostic and therapeutic solutions, high healthcare expenditure, and the presence of leading players are expected to boost the American porokeratosis treatment market.


Europe holds the second position in the porokeratosis treatment market. It is expected that the rising contribution of various marketers is likely to drive the European porokeratosis treatment market. For instance, in July 2016, Chugai and Galderma announced the global license agreement for the development and marketing of Nemolizumab worldwide. The Nemolizumab is a novel biologic for skin diseases.


Asia Pacific is the fastest growing porokeratosis treatment market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. In this region, the Mibelli type is most frequent as compared to other types. In Singapore, the Mibelli type of porokeratosis was present in 56% of the porokeratosis patients in 2013, suggested by a study published in the Cases in Dermatology Journal.


The Middle East and Africa holds the lowest share of the global porokeratosis treatment market due to the presence of poor and slow developing countries, especially, in the African region.


Research Methodology


Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


The extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the porokeratosis treatment market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.


Global Porokeratosis Treatment Market, by Type



  • Disseminated actinic porokeratosis

  • Linear porokeratosis

  • Porokeratosis of Mantoux

  • Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)

  • Punctate porokeratosis


Global Porokeratosis Treatment Market, by Diagnosis & Treatment



  • Diagnosis

  • Biopsy

  • Differential Diagnosis

  • Squamous cell carcinoma

  • Lichenoid keratosis

  • Epidermal nevus

  • Others

  • Treatment

  • Topical Diclofenac

  • Ingenol Mebutate

  • Topical Vitamin D analog

  • 3-Fluorouracil

  • Immunomodulators

  • Imiquimod

  • Resiquimod

  • Photodynamic Therapy

  • Retinoids

  • Topical retinoids

  • Oral retinoids

  • Cryotherapy

  • Lasers

  • Immunosuppressive Agents

  • Calcineurin inhibitors

  • Others

  • Others


Global Porokeratosis Treatment Market, by End-User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Drug Stores

  • Research and academic institutes

  • Others


Global Porokeratosis Treatment Market, by Region



  • Americas

  • North America

  • U.S.

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • U.K.

  • Rest of Western Europe

  • Eastern Europe

  • Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Company Profiles       



  • Angiodynamics, Inc.

  • Alma Lasers

  • Allergan

  • Beiersdorf AG

  • BIONESS, INC

  • Biogen

  • Biolase Inc.

  • Coherent, Inc.

  • COTY INC.

  • Cutera

  • Hoffmann-la Roche ltd

  • Danaher Corporation

  • HOLOGIC INC.

  • PFIZER


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023: 6%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnostic and Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Angiodynamics, Inc. (U.S.), Allergan (Republic of Ireland), Alma Lasers (Israel), Beiersdorf AG (Germany), Biogen (U.S.), Biolase Inc. (U.S.), Coherent, Inc. (U.S.), Coty Inc. (U.S.), Cutera (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (U.S.), IPG Photonics Corporation (U.S.), IRIDEX Corp. (U.S.), L’Oreal (France), Lumenis (U.S.), Pfizer (U.S.), PhotoMedex, Inc. (U.S.), Valeant Pharmaceuticals (Canada), and others.
  Key Market Opportunities

  • Rising cases of renal transplant
  • Improved reimbursement policies in developed countries
  • Growing research funding, and rising competition
  •   Key Market Drivers   The rising number of renal transplants


    Frequently Asked Questions (FAQ) :


    Porokeratosis is a rare skin condition presenting as small, round patches on the skin. In a small number of cases, these patches may develop into skin cancer.

    Global Porokeratosis Market is expected to exhibit a strong 6% CAGR over the forecast period from 2018 to 2027.

    The rising number of renal transplants is the major driver for the porokeratosis market.

    The Americas dominate the global Porokeratosis Market.

    Leading players in the Porokeratosis Market include Alma Lasers, Coherent Inc., and Biogen, among others.